SavedAdd your journal

Journals / Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2017 / Cilt: 50 - Sayı: 3

DOES ANTI-MULLERIAN HORMONE LEVEL VARY AT DIFFERENT RECOMBINANT FSH DOSES?

ANTI-MÜLLERYEN HORMON SEVİYESİ FARKLI RECOMBİNANT FSH DOZLARI İLE DEĞİŞİR Mİ?

Berna DİLBAZ
Serdar DİLBAZ
Yetkin KARASU
Berfu DEMİR
Pages
136–141
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Total gonodotropin dose used was higher in the PCOS patients (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to compare intracycle variability of Anti-Mullerian Hormone (AMH) throughout controlled ovarian hyper stimulation (COH) with follicle stimulating hormone (FSH) treatment in women with Polycystic Ovary Syndrome (PCOS) and normoresponder infertile patients.
📊
Key Findings & Data:Infertile PCOS (n=30) patients were grouped into two.
💡
Conclusion & Impact:Total gonodotropin dose used was higher in the PCOS patients (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to compare intracycle variability of Anti-Mullerian Hormone (AMH) throughout controlled ovarian hyper stimulation (COH) with follicle stimulating hormone (FSH) treatment in women with Polycystic Ovary Syndrome (PCOS) and normoresponder infertile patients. Infertile PCOS (n=30) patients were grouped into two. In the first group 15 patients were treated with long luteal gonadotropin releasing hormone analogue (GnRHa) and invitro fertilization (IVF) and 15 PCOS patients were treated with COH-intrauterine insemination (IUI). Non-PCOS (n=30) patients were treated with COH-IUI. AMH was measured three times in all groups (basal, mid-cycle, luteal). AMH levels in PCOS and non-PCOS patients underwent different amount of exogenous FSH treatment were compared. AMH levels in the PCOS patients were 2-2.5 times higher than non-PCOS patients. Total gonodotropin dose used was higher in the PCOS patients (p

Özet

Bu çalışmanın amacı polikistik over sendromlu (PCOS) ve normoresponder hastalarda follikül stimule edici hormone (FSH) tedavisinin anti-mülleryen hormone (AMH) seviyelerini etkileyip etkilemediğini araştırmaktır. Bu amaçla PCOS'li infertil hastalar (n=30) iki gruba ayrıldı. Birinci gruba long luteal gonodotropin releasing hormon (GnRH) ve invitrofertilizasyon (IVF) (n=15) diğer gruba ise kontrollü overyen hiperstimulasyon ve intrauterin inseminasyon (COH-IUI) tedavisi uygulandı. Normoresponder non-PCOS (n=30) hasta grubu da COH-IUI tedavisi aldı. Tüm gruplarda AMH düzeyleri siklus içinde 3 kez ölçüldü (bazal, midsiklus, luteal). PCOS'li ve non-PCOS'li hastalarda AMH seviyesinin farklı FSH dozlarından etkilenip etkilenmediği araştırıldı. Kullanılan total gonadotropin dozu PCOS'li hastalarda daha yüksekti (p

🔖

Cite This Article

DİLBAZ, B., DİLBAZ, S., KARASU, Y., DEMİR, B. (2022). DOES ANTI-MULLERIAN HORMONE LEVEL VARY AT DIFFERENT RECOMBINANT FSH DOSES?. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 50 - Sayı: 3, 136–141. https://ajindex.com/articles/441336

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998
  2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004
  3. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril. 1997
  4. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007
  5. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008
  6. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004
  7. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010
  8. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002
  9. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004
  10. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D.Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003
  11. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006
  12. Wunder DM, B